Symproic (Naldemedine Tosylate) Patent Expiration, LOE Window & CMS Spending

Symproic (Naldemedine Tosylate) by Biodelivery Sciences International: FDA Orange Book core substance LOE 2033-05-13, 0 AB generics, $12.4M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiodelivery Sciences International
FDA Application & PathwayN208854 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-05-13
Last Listed Patent or Exclusivity Date2033-05-13
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12.4M
2024 Medicare Part D Spend$9.8M
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.9% 2-yr change)